Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMMURAVID: Remdesivir and Baricitinib for Moderate COVID-19
NCT04832880Phase 3Unknown
- Sponsor
- ASST Fatebenefratelli Sacco
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of remdesivir, baricitinib in coronavirus disease 2019 (COVID-19), sponsored by ASST Fatebenefratelli Sacco. Status: unknown.
02
Drugs
remdesivirbaricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04832880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832880.